CSI Market
Sign In | Register

Alaunos Therapeutics Inc (TCRT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TCRT quarterly Cash Flow →
A period-by-period view of cash flow from Alaunos Therapeutics Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-8.46
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.80
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.03
Employee Benefits And Share Based Compensation Noncash0.44
Derivative Gain Loss On Derivative Net-
Non Operating Income Expense Inducement Of Warrants-
Increase Decrease In Operating Deposits-
Increase Decrease In Lease Liabilities-
Income taxes0.30
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable0.10
Increase (Decrease) in Accrued Liabilities0.02
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.35
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-2.87
Investing Activities
Capital Expenditures-0.10
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.10
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock And Warrants Net-
Payment For Issuance Of Restricted Common Stock-
Proceeds From Underwritten Financing-
Sale Of Stock Consideration Received On Transaction-
Net Proceeds From At The Market Stock Offering-
Proceeds From The Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs-
Proceeds From Sale Of Series A-1 Preferred Stock-
Proceeds From Sale Of Series A-2 Preferred Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.26
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.97
Total Cash Flow0.29
4 historic quarters locked

Sign in to unlock the full Alaunos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Alaunos Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-134720

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License